This manual applies to all DAIDS-supported and/or -sponsored clinical trials, unless the DAIDS Office for Policy in Clinical Research Operations (OPCRO) Director or designee has delegated the responsibility for expedited adverse event (EAE) reporting to another entity (e.g., a pharmaceutical or investigator-sponsor).
Document Date
Tuesday, September 11, 2018